- |||||||||| AVID100 / BMS
Enrollment change, Trial termination, Metastases: AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov) - Mar 24, 2021
P1a, N=49, Terminated,
N=90 --> 49 | Active, not recruiting --> Terminated; lack of efficacy
- |||||||||| AVID100 / BMS
Enrollment closed, Metastases: AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov) - Oct 23, 2020
P1a, N=90, Active, not recruiting,
N=90 --> 49 | Active, not recruiting --> Terminated; lack of efficacy Recruiting --> Active, not recruiting
- |||||||||| AVID100 / BMS
Trial completion date, Trial primary completion date, Metastases: AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov) - Aug 30, 2019
P1a, N=90, Recruiting,
The prospective Phase 2a trial assessing AVID100, a novel growth factor receptor function-blocking anti-EGFR ADC, remains ongoing and updated results will be presented at the meeting. Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- |||||||||| AVID100 / BMS
Enrollment change, Trial completion date, Trial primary completion date, Metastases: AVID100 in Advanced Epithelial Carcinomas (clinicaltrials.gov) - Jan 23, 2019
P1a, N=90, Recruiting,
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 N=30 --> 90 | Trial completion date: Aug 2019 --> Jun 2020 | Trial primary completion date: Apr 2019 --> Sep 2019
|
